Merck reports third quarter 2026 earnings results after muted trading session

Traders Union
All News
Business & Wealth
Companies
Merck stock edges lower to $141.13

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

Anton Kharitonov

29.10.2026

Merck reports third quarter 2026 earnings results after muted trading session — Merck stock edges lower to $141.13

Merck released its third quarter 2026 earnings results. The stock edges lower on the day, trading at $141.13.

MRK price prediction

24H 0.05%

€151.33

48H -0.11%

€151.08

7D -0.31%

€150.78

1M 8.09%

€163.48

3M 17.24%

€177.33

6M 6.23%

€160.67

12M 29.9%

€196.48

Current price: €151.25 0.9500 0.63%

Closed 10/30

Daily range 150.50

152.05

Weekly range 142.05

152.05

Loading...

Highlights

Merck released its third quarter 2026 earnings results as Chairman and CEO Rob Davis issued remarks on company performance.
77 of 110 analysts rate Merck stock a buy with a median price target of $163, 15.4% above current levels.
Merck stock edges lower on the day, trading at $141.13.

Merck reported its earnings results for the third quarter of 2026. The announcement came directly from the company, accompanied by comments from Chairman and CEO Rob Davis. Merck operates in the general drug manufacturing sector, has 73,000 employees, and holds a market value of around $359.22 billion on trailing revenue of $66.56 billion.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Mixed structure holds as shares gap down then recover above MA-200

Shares of Merck opened with a gap down from $141.82 to $140 before recovering some of that early loss. Price action takes place below the MA-20 and MA-50 but remains above the MA-200, reflecting a split daily structure. The nearest support sits at the weekly low of $139.21, while Stoch RSI in oversold territory suggests limited room for further downside.

Downside odds lead as traders monitor $139.21 support risk

To assess whether the recent news is being reflected in the price, traders should watch for a close above $144.22 or a loss of support at $139.21. The session began with a break lower from $141.82 to $140, and shares have since reclaimed a portion of that decline. Despite a sharp move lower over the past week without a sustained trend, downside probability is seen at 60% versus 40% for upside over the coming trading week, with an expected range of $134.53 to $147.72. A daily close above $144.22 would indicate buyers are stepping in, while a drop below $139.21 would show renewed weakness. On the weekly chart, the longer-term picture remains constructive.

Previously it was reported that Merck's TROP2-directed antibody-drug conjugate trial results added a potential catalyst, while technical signals indicated a mixed outlook for the shares. With the latest earnings release and current price action below key moving averages but above major support, traders should watch for a move outside the $139.21 to $144.22 range to signal the next directional shift.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Merck

Editor's Picks for You

DeFi for the select few: Why Hyperliquid is building restricted markets

By Pavlo Kot
Yesterday

DeFi for the select few: Why Hyperliquid is building restricted markets

Editors' Picks

Can Bitcoin make you a millionaire?

By Pavlo Kot
Yesterday

Can Bitcoin make you a millionaire?

Editors' Picks

France's crypto market matures as regulation reshapes the industry

By Olena Litvinenko
30.10.2026

France's crypto market matures as regulation reshapes the industry

Editors' Picks

All Editors' Top Picks

Latest Merck News

Merck announces endometrial cancer trial findings while stock falls 2.3%

By Parshwa Turakhiya
26.10.2026

Merck announces endometrial cancer trial findings while stock falls 2.3%

Companies

Merck announces positive Phase 3 data for neoantigen therapy: Can MRK break above $149.98?

By Andrey Mastykin
22.10.2026

Merck announces positive Phase 3 data for neoantigen therapy: Can MRK break above $149.98?

Companies

Merck announces topline results from Phase 2b/3 study in diabetic macular edema after stock ends session down 1.8%

By Sergey Shendetskyi
24.09.2026

Merck announces topline results from Phase 2b/3 study in diabetic macular edema after stock ends session down 1.8%

Companies

Pavlo Kot
Yesterday

DeFi for the select few: Why Hyperliquid is building restricted markets

Pavlo Kot
Yesterday

Can Bitcoin make you a millionaire?

Olena Litvinenko
30.10.2026

France's crypto market matures as regulation reshapes the industry

Dmytro Kharkov
30.10.2026

SK Hynix’s rise reshapes the global chip industry and economy

Eugene Komchuk
30.10.2026

Binance hack: The biggest theft in crypto history

Ksenia Gerey
1 hour ago

Authorities increase oversight of offshore crypto cards, Pushpendra Singh reports

Hanna Syniavska
1 hour ago

Michael Pettis: Pudong model generated GDP growth but relied on extractive transfers

Alena Volkova
3 hours ago

Howard Lindzon: Calls for greater scrutiny of DJT and certain figures

Daria Chernytska
3 hours ago

Using multi-sig across hardware and software helps manage unknown risks, Stephan Livera notes

Yaroslav Dmytrenko
3 hours ago

Lia Holmgren: QQQ sees 650 put with 30,935 open interest as hedge, not short term trade

Top News

Jose Antonio Gastelum
19 hours ago

OPEC set to hold oil quotas as Middle East risks constrain supply

OPEC set to hold oil quotas as Middle East risks constrain supply

Ezequiel Gomes
21 hours ago

Big Tech selloff drives investors back toward U.S. Treasuries

Big Tech selloff drives investors back toward U.S. Treasuries

Sholanke Dele
21 hours ago

Binance resumes crypto withdrawals after $6.3B hack

Binance resumes crypto withdrawals after $6.3B hack

Pavlo Kot
Yesterday

DeFi for the select few: Why Hyperliquid is building restricted markets

DeFi for the select few: Why Hyperliquid is building restricted markets

Ivan Andriyenko
Yesterday

Apple overtakes Nvidia as world's most valuable company with market cap above $5 trillion

Apple overtakes Nvidia as world's most valuable company with market cap above $5 trillion

Top 5 companies for you

United States

Live News

Andrey Mastykin
Now

Eurozone economy slows as France slips into recession fears

Anton Kharitonov
Now

EUR/USD recovery stalls near 1.1210 as dollar retains its fundamental advantage

Anastasiia Chabaniuk
Now

Binance launches stolen asset recovery and allocates $6.34 billion to cover losses

Mykhailo Ihnatenko
Now

AMD stock drops over 7% as Intel outlook hits semiconductor sentiment

Jose Antonio Gastelum
Now

Circle phases out old USDC bridge as CCTP V2 takes over

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.